Intravenous versus Oral Corticosteroids for Treatment of Acute Asthma Exacerbations

2002 ◽  
Vol 36 (4) ◽  
pp. 565-570 ◽  
Author(s):  
Patricia Pecora Fulco ◽  
Amista A Lone ◽  
Carol B Pugh

OBJECTIVE: To compare the duration of hospitalization of patients treated with either oral or intravenous corticosteroids for an acute asthma exacerbation. METHODS: A retrospective chart review was performed on a random sample of inpatients. Patients were included with the following: a discharge diagnosis of an acute asthma exacerbation, a past medical history significant for asthma, age between 16 and 60 years, and treatment with either oral or intravenous corticosteroids at the time of admission. Exclusion criteria included: patients receiving chronic prednisone therapy, a past medical history significant for chronic obstructive pulmonary disease, an admission to the intensive care unit, or a consistent smoking habit of at least 1 pack daily. Length of hospitalization was the primary outcome measured. Secondary outcomes included 24-hour peak expiratory flow rate, 24-hour pulse oximetry (pO2), and amount of β-agonist and ipratropium used. RESULTS: Fifty-three patients were included in the final data analysis. Patients were grouped by route of corticosteroid administration (intravenous or oral). No significant differences were noted between the 2 groups for race, gender, age, height, weight, admission peak expiratory flow rate, admission pO2, or types of asthma medications used prior to admission. No significant differences were demonstrated in any of the outcome measures. CONCLUSIONS: Both the intravenous and oral corticosteroid groups demonstrated similar clinical outcomes and lengths of hospitalization in the treatment of acute asthma exacerbations. These results support the initial use of oral corticosteroids for the treatment of acute asthma exacerbations in adult patients admitted to a general medical service.

2013 ◽  
Vol 4 (3) ◽  
pp. ar.2013.4.0062 ◽  
Author(s):  
Hiroto Matsuse ◽  
Tomoko Tsuchida ◽  
Susumu Fukahori ◽  
Tetsuya Kawano ◽  
Shinya Tomari ◽  
...  

Upper respiratory tract infections (URIs) represent the most frequent cause of acute asthma exacerbations. It has yet to be determined whether leukotriene receptor antagonist (LTRA) treatment prevents URI-induced acute asthma exacerbations in adults. The objective of the present study was to evaluate the preventive effects of LTRA treatment on URI-induced acute asthma exacerbations. The incidences of URI alone, acute asthma exacerbation without URI, and URI-induced acute asthma exacerbation were determined retrospectively by analyzing diary and medical records of 321 adult asthmatic patients (mean age, 56.3 ± 17.2 years; male/female ratio, 117:204) over 1 year. Results were compared between patients who had been taking an LTRA (n = 137) and those who had never taken any LTRA (n = 184) during the study periods. Significantly fewer URIs alone and acute asthma exacerbations without URI occurred in patients with than in those without prophylactic daily use of LTRA. LTRA treatment significantly reduced the durations of URIs alone and of total acute asthma exacerbations, as well as the incidence of mild exacerbations of asthma. In contrast, in patients with URI-induced acute asthma exacerbations, LTRA treatment failed to significantly reduce the interval between URI onset and acute asthma exacerbation, as well as the duration and severity of both URIs and acute asthma exacerbations. Use of an LTRA for adult asthmatic patients appears to reduce the incidences of URIs alone and acute asthma exacerbations without URI, but it failed to prevent URI-induced acute asthma exacerbations once a URI occurred.


2017 ◽  
Vol 22 (4) ◽  
pp. 190-194 ◽  
Author(s):  
Neale Smith ◽  
Anne Smith ◽  
Alice Wang ◽  
Kaitlyn Shaw ◽  
Gabriella Groeneweg ◽  
...  

2018 ◽  
Vol 66 (8) ◽  
pp. 1102-1108 ◽  
Author(s):  
Noussa Ragab El Basha ◽  
Hanan Mohsen Osman ◽  
Amaal Abdo Abdelaal ◽  
Salma Mohamed Saed ◽  
Hala Hamdy Shaaban

Children with severe asthma or acute asthma exacerbation may encounter difficulties in performing pulmonary function tests. In this situation, serum biomarkers can play a great role in evaluation of such patients. The aim of this study was to estimate the serum levels of human chitinase-3-like protein 1 (YKL40) and periostin in a group of Egyptian children with asthma during acute asthma exacerbation and in stable asthmatics compared with healthy control, and to correlate these findings with the severity of asthma. This cross-sectional study enrolled 120 childrenwith asthma with different degrees of asthma severity, according to the Global Initiative for Asthma guidelines, along with 60 age-matched and sex-matched healthy control. A complete blood count and an estimation of serum periostin and YKL40 levels were performed for all cases and control. Individual and mean values of periostin and YKL40 were significantly higher during acute asthma exacerbations, p<0.001. A highly significant relation between serum levels of periostin and YKL40 and asthma severity, p value for each was <0.001. Absolute eosinophil count was significantly correlated with the serum periostin levels in stable asthmatic group (p=0.01) only. There was significantly positive correlation (P<0.001) between both markers in stable asthmatic group. Spearman’s correlation coefficient shows a statistically significant positive correlation between both markers and patient’s age and duration of asthma, p value for each was 0.001. These findings highlight the importance of periostin and YKL40 as serum biomarkers for assessment of asthma severity and acute asthma exacerbations in children with asthma.


Author(s):  
Ashok Kumar

Background: Although the treatment of acute asthma in the emergency department varies, the administration of magnesium sulfate (MgSO4) is usually recommended adjacent to corticosteroids and bronchodilators. This study aims to ascertain the influence of inhaled MgSO4 as complement treatment with salbutamol regarding treatment of urgent asthma exacerbations. Methods: A single-blind randomized control study was carried out, from 1st January 2017 to 30th June 2017, involving asthmatic patients presenting to Ziauddin Hospital and Jinnah Hospital in Karachi, with severe acute asthma exacerbations. The Sealed Envelope calculator was used to calculate a sample size of 84 patients, and data was collected through non-probability consecutive sampling. Both batches were administered salbutamol and ipratropium, with Batch A patients also receiving nebulization with MgSO4. Dyspnea, respiratory rate, pulse, peak expiratory flow rate, and oxygen saturation were recorded for each participant. An independent sample t-test was used to assess the effectiveness of MgSO4, as a significant means of improving asthma treatment, with a p<0.05 interpreted as significant. Results: A sum of 115 patients was included in the research, out of which 63.5% had a family history of asthma. Treatment with MgSO4 was seen as significant (p<0.01). MgSO4 administration showed significant improvement in mean pulse rate (p = 0.001), peak expiratory flow rate (p = 0.004) and mean respiratory rate (p = 0.003), as compared to treatment with salbutamol only. Conclusion: Treatment outcomes between the two groups differed significantly. Intervention with MgSO4 showed significant improvement in pulse rate, respiratory rate, dyspnea, and peak flow, without any observed side effects.


Sign in / Sign up

Export Citation Format

Share Document